zopapogene imadenovec

**Zopapogene imadenovec** is a non-replicating gorilla adenovirus vector-based immunotherapy developed by Precigen for adults with recurrent respiratory papillomatosis, a chronic disease driven by human papillomavirus type 6 or type 11. The vector expresses a fusion antigen containing selected epitope regions from HPV-6 and HPV-11 E2, E4, E6, and E7 proteins, with the goal of inducing HPV-specific cellular immune responses against papilloma cells. It is marketed in the United States as PAPZIMEOS and was approved by the FDA on August 14, 2025, as a subcutaneous treatment for adult recurrent respiratory papillomatosis. ([precision.fda.gov](https://precision.fda.gov/ginas/app/ui/substances/3518862e-ae07-447f-a184-b972ff5c29c7))

Brand names

PAPZIMEOS

Other names

replication-deficient gorilla adenovirus vector (strain GC46) encoding human papillomavirus type 6 and type 11 antigenszopazopapogene imadenovec-drba